購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
Chronic-PKD Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
Chronic-PKD Mouse
製品名
Chronic-PKD Mouse
製品ID
C001974
系統名
C57BL/6Cya-Pkd1em1floxCdh16em1(IRES-MerCreMer)/Cya
背景情報
C57BL/6Cya
状況
このマウス系統を論文で使用する場合は、「Chronic-PKD Mouse(カタログ番号C001974)はサイアジェンから購入しました。」と引用してください。
Disease Animal Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Disease Animal Models
基本情報
検証 Data
関連リソース
基本情報
遺伝子名
遺伝子別名
PC1, mFLJ00285
NCBI ID
染色体
Chr 17
MGI ID
さらに
系統詳細
Polycystin-1 (PC1), encoded by the PKD1 gene, is a large transmembrane glycoprotein that orchestrates critical cellular processes—including cell–cell and cell–matrix interactions, calcium signaling, and mechanosensation—in renal tubular epithelial cells. PC1 regulates various aspects of cellular function, including signal transduction, cytoskeletal remodeling, and cell adhesion. It forms a functional complex with Polycystin-2 (PC2), the product of the PKD2 gene, to maintain intracellular calcium homeostasis and facilitate mechanotransduction [1]. Disruption of PC1 signaling, due to PKD1 mutations—which account for approximately 85% of autosomal dominant polycystic kidney disease (ADPKD) cases—undermines these regulatory pathways, promoting abnormal cell proliferation and cyst formation [2]. Clinically, ADPKD is characterized by the progressive development of multiple fluid-filled cysts, renal enlargement, hypertension, and eventual progression to end-stage kidney disease (ESKD). With a global incidence estimated at 1 in 400 to 1 in 1000 individuals, ADPKD affects nearly 500,000 people in the United States alone and frequently involves extra-renal manifestations, including the heart, liver, pancreas, spleen, and arachnoid membrane [3]. Notably, genotypic heterogeneity exists, with PKD1 mutations often associated with an earlier onset and more aggressive disease course [2-3].
Traditional systemic Pkd1 knockout models are typically embryonically lethal, precluding long-term pathogenesis studies. In contrast, inducible, kidney-specific conditional knockout models using the Cre-LoxP system recapitulate the clinical features of human ADPKD and permit the investigation of disease progression in adult mice [4-5]. Chronic-PKD mice are an inducible conditional Pkd1 knockout model generated by crossing Pkd1-flox mice with kidney-specific, tamoxifen-inducible Cre mice (Cdh16-MerCreMer mice). Preliminary data show that palpable renal enlargement occurs at 6 weeks after tamoxifen induction. At 10 weeks post-induction, a polycystic kidney phenotype is visible upon dissection, with no mortality observed and a more pronounced phenotype in male mice. We will continue monitoring this model to characterize late-stage phenotypes and the overall disease progression.
参考文献
Su Q, Hu F, Ge X, Lei J, Yu S, Wang T, Zhou Q, Mei C, Shi Y. Structure of the human PKD1-PKD2 complex. Science. 2018 Sep 7;361(6406):eaat9819.
Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 2009;60:321-37.
Mahboob M, Rout P, Leslie SW, et al. Autosomal Dominant Polycystic Kidney Disease. [Updated 2024 Mar 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
Sieben CJ, Harris PC. Experimental Models of Polycystic Kidney Disease: Applications and Therapeutic Testing. Kidney360. 2023 Aug 1;4(8):1155-1173.
Happé H, Peters DJ. Translational research in ADPKD: lessons from animal models. Nat Rev Nephrol. 2014 Oct;10(10):587-601.
系統作製戦略
Chronic PKD(inducible) was generated by crossing Pkd1‑flox mice with kidney‑specific, tamoxifen‑inducible Cre mice (Cdh16‑MerCreMer mice, catalog No.: C001432). For detailed information on Cdh16‑MerCreMer mice, please refer to the strain datasheet. The gene‑editing strategy for Pkd1‑flox mice is shown below.

Figure 1. Gene editing strategy for Pkd1-flox mice. Exons 2–8 of the mouse Pkd1 gene serve as the conditional knockout (cKO) region.
適用分野
Research on renal tubular calcium homeostasis and mechanotransduction;
Research on renal tubular structure, function, and signal transduction;
Research on autosomal dominant polycystic kidney disease (ADPKD);
Research on other renal diseases.
検証 Data
1. Experimental Protocol and Induction Regimen for Chronic Polycystic Kidney Disease
Pkd1flox/flox;Cdh16-MerCreMer[KI/KI] mice were divided into three groups: Group 1 (G1) served as the corn oil vehicle control, while Group 2 (G2) and Group 3 (G3) were induced with Tamoxifen (TAM) at dosages of 100 mg/kg and 200 mg/kg, respectively. All mice received daily intraperitoneal (i.p.) injections for 5 consecutive days starting at approximately 3 weeks of age. Serum and urine samples were collected at weeks 2, 4, 6, 8, and 10 post-induction for biochemical analysis. The study was terminated at week 10, at which point kidneys were harvested and weighed for subsequent analysis, including the determination of kidney weight, kidney index, and histopathological examination.

Figure 2. Experimental schematic and induction regimen.
2. Renal Phenotype (Gross Appearance and Kidney Index)
Results indicated that kidney weight and organ index were significantly increased in male mice from the G2 (100 mg/kg TAM) and G3 (200 mg/kg TAM) groups compared to controls. In female mice, these parameters showed an increasing trend but did not reach statistical significance. (Bars represent Mean ± SD, Two-way ANOVA, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.)

Figure 3. Renal phenotype of Pkd1flox/flox;Cdh16-MerCreMer[KI/KI] mice at 10 weeks post-Tamoxifen (TAM) induction (n=3~7).
(A) Gross appearance of kidneys from each group at 10 weeks post-induction.
(B) Quantitative analysis of renal effects 10 weeks after induction with 100 mg/kg and 200 mg/kg TAM, assessing left and right kidney weights and kidney index (percentage of total kidney weight to body weight).
3. Histopathological Observation
Results demonstrated that both G2 (100 mg/kg TAM) and G3 (200 mg/kg TAM) induction regimens successfully elicited a polycystic kidney phenotype in both male and female mice. Compared to the G1 (Corn Oil) group, the Cystic Index and Cyst Density were significantly elevated in both G2 and G3 groups. Notably, the G3 group exhibited higher values than G2, indicating a dose-dependent effect. Furthermore, males in the G3 group showed higher indices than females, suggesting that the dose-dependent response to TAM induction is more pronounced in male mice. (Bars represent Mean ± SD, Two-way ANOVA, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Figure 4. Renal pathology of Pkd1flox/flox;Cdh16-MerCreMer[KI/KI] mice at 10 weeks post-Tamoxifen (TAM) induction (n=3~7).
(A) Representative H&E staining images of kidneys from each group at 10 weeks post-induction. Black arrows indicate renal cysts.
(B) Quantitative analysis of Cystic Index and Cyst Density at 10 weeks post-induction. Cystic Index: percentage of cystic area to total area (%); Cyst Density: number of cysts per unit renal area (NO./mm²).
Scale bars: 2 mm (low magnification); 200 μm (high magnification).
4. Body Weight and Biochemical Indicators
(1)Male
Throughout the study, body weight in all groups showed a steady increase; however, G2 (100 mg/kg TAM) and G3 (200 mg/kg TAM) males exhibited lower weights compared to the G1 (Corn Oil) group, suggesting an association between polycystic kidney progression and mild growth retardation. Over time, urine UACR, serum BUN, and serum CREA levels in G2 and G3 groups showed an upward trend relative to G1, with a more pronounced elevation observed in G3. At 10 weeks post-induction, urine UACR in G3 males was significantly elevated compared to G1, while serum BUN and CREA levels showed an increasing trend without statistical significance. Bars represent Mean ± SD, t-test, ns indicates no statistical significance (P>0.05), ****P<0.0001.

Figure 5. Monitoring of body weight, urinary, and serum biochemical parameters in Pkd1flox/flox;Cdh16-MerCreMer[KI/KI] mice at 10 weeks post-Tamoxifen (TAM) induction (male, n=3).
(A) Growth curves of male mice in each group.
(B) Urinary albumin-to-creatinine ratio (UACR) at weeks 2, 4, 6, 8, and 10 post-TAM induction.
(C-D) Serum Blood Urea Nitrogen (BUN) levels (C) and Creatinine (CREA) levels (D) at weeks 2, 4, 6, 8, and 10 post-TAM induction.
(E) Comparison of urine UACR, serum BUN, and serum CREA levels between G1 (Corn Oil) and G3 (200 mg/kg TAM) males at 10 weeks post-induction.
(2)Female
Throughout the study, body weight in all female groups increased steadily with no significant differences, indicating that the progression of polycystic kidney disease did not impact somatic growth in females. Over time, urine UACR levels in G2 (100 mg/kg TAM) and G3 (200 mg/kg TAM) groups were elevated compared to the G1 (Corn Oil) group, whereas serum BUN and CREA levels remained comparable to controls. At 10 weeks post-induction, urine UACR in G3 females was significantly higher than in G1, while serum BUN and CREA levels showed no statistically significant difference. (Bars represent Mean ± SD, t test, ns indicates no statistical significance (P>0.05), *P<0.05.

Figure 6. Monitoring of body weight and renal function in Pkd1flox/flox;Cdh16-MerCreMer[KI/KI] mice at 10 weeks post-Tamoxifen (TAM) induction (female, n=3).
(A) Growth curves of female mice in each group.
(B) Urinary albumin-to-creatinine ratio (UACR) at weeks 2, 4, 6, 8, and 10 post-TAM induction.
(C-D) Serum Blood Urea Nitrogen (BUN) levels (C) and Creatinine (CREA) levels (D) at weeks 2, 4, 6, 8, and 10 post-TAM induction.
(E) Comparison of urine UACR, serum BUN, and serum CREA levels between G1 (Corn Oil) and G3 (200 mg/kg TAM) females at 10 weeks post-induction.
5. Model Summary
In conclusion, Tamoxifen (TAM) induction successfully elicited a polycystic kidney phenotype in Pkd1flox/flox;Cdh16-MerCreMer[KI/KI] mice, with renal injury severity exhibiting a clear dose-dependent manner. Compared to the low-dose group (G2, 100 mg/kg), the high-dose group (G3, 200 mg/kg) displayed a more pronounced phenotype, characterized by significantly greater elevations in kidney weight, kidney index, cystic index, and cyst density. Furthermore, the G3 group showed more marked increases in urinary albumin-to-creatinine ratio (UACR) and a stronger upward trend in renal function markers (BUN, CREA) throughout the study.
Additionally, the model exhibited significant sexual dimorphism: male mice experienced mild growth retardation, whereas females maintained normal growth. The severity of cyst formation, renal impairment (UACR), and the dose-dependent response were all more pronounced in males than in females. Therefore, to establish a robust model with a stable and significant phenotype, we recommend inducing 3-week-old male Pkd1 conditional knockout mice with a 200 mg/kg dose of Tamoxifen.
関連リソース
お問い合わせ
ご不明な点やご質問などございましたら、お気軽にお問い合わせください。担当スタッフがサポートさせていただきます。下記のフォームにご記入いただければ、1〜2営業日以内に折り返しご連絡いたします。
Related Product
All Related ProductsResources
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
